
|Articles|January 4, 2007
Repeated dosing of radiopharmaceutical found safe, effective in PCa patients with bone mets
Repeated doses of the targeted radiopharmaceutical samarium Sm-153 lexidronam injection (Quadramet) are a safe and effective treatment option in patients with painful bone metastases secondary to prostate cancer, according to a multicenter, phase IV study published recently in the online edition of Cancer.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to Enolen for localized prostate cancer
2
High PHI scores are linked to increased odds of significant prostate cancer
3
Trial to evaluate novel combination in BCG-unresponsive NMIBC
4
Dosing begins in trial of alpha radioligand therapy for mCRPC
5




















